|
|
Volumn 332, Issue 6029, 2011, Pages 523-
|
|
Shortages of cancer drugs put patients, trials at risk
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
BUSULFAN;
CISPLATIN;
CYTARABINE;
DOXORUBICIN;
ETOPOSIDE;
FOLINIC ACID;
GENERIC DRUG;
VINCRISTINE;
BLOOD SYSTEM DISORDER;
CANCER;
DISEASE TREATMENT;
DRUG;
HOSPITAL SECTOR;
RISK ASSESSMENT;
ACUTE GRANULOCYTIC LEUKEMIA;
ANESTHESIST;
CANCER CHEMOTHERAPY;
CHILDHOOD LEUKEMIA;
DRUG INDUSTRY;
DRUG MANUFACTURE;
DRUG SAFETY;
DRUG SHORTAGE;
FOOD AND DRUG ADMINISTRATION;
HEALTH CARE SYSTEM;
HODGKIN DISEASE;
HUMAN;
MEDICAL SOCIETY;
PHARMACIST;
PRIORITY JOURNAL;
SHORT SURVEY;
TESTIS CANCER;
UNITED STATES;
CLINICAL TRIAL (TOPIC);
ECONOMICS;
LEGAL ASPECT;
NOTE;
ANTINEOPLASTIC AGENTS;
CLINICAL TRIALS AS TOPIC;
DRUG INDUSTRY;
DRUGS, GENERIC;
HUMANS;
UNITED STATES;
|
|
EID: 79955529075
PISSN: 00368075
EISSN: 10959203
Source Type: Journal
DOI: 10.1126/science.332.6029.523 Document Type: Short Survey |
|
Times cited : (36)
|
|
References (0)
|
